Share

    


Home / Search Results

Search Results

Search Publications

Search Again?

Filter By Content Type

Filter By Topic

Emily Westergard, DO, et al., Abbott Northwestern Hospital, Minneapolis, MN View Poster
Takuto Takahashi, MD et al., University of Minnesota, Minneapolis, MN View Poster
Haixia Qin, MD/PhD et al., University of Minnesota, Minneapolis, MN View Poster
Grigori Okoev, MD, PhD, et al., University of Minnesota, Minneapolis, MN View Poster
Bhaskar Kolla, MBBS, et al., University of Minnesota, Minneapolis, MN View Poster
Brittany Kimball, MD, MD, et al., University of Minnesota, Minneapolis, MN View Poster
Marie Hu, MD, et al., University of Minnesota, Minneapolis, MN View Poster
Robert T. Galvin, MD, et al., University of Minnesota, Minneapolis, MN View Poster
Asmaa Ferdjallah, MD, et al., University of Minnesota, Minneapolis, MN View Poster
Ashley Draisey , DO, et al., Abbott Northwestern Hospital, Minneapolis, MN View Poster
Austin Cudak DO, et al., University of Minnesota, Minneapolis, MN View Poster
Jeremy Allred, MD, et al., University of Minnesota, Minneapolis, MN View Poster
PowerPoint Presentation Busulfan Dose Recommendation in Inherited Metabolic Disorders: Population Pharmacokinetic Analysis Takuto Takahashia,b, Silvia M. Illamolab, Cathryn A. Jennissenc, Susan E. Longc, Troy C. Lunda, Paul J. Orcharda, Janel R. Long-Boyled, Ashish O. Guptaa aDivision of Pediatric Hematology/Oncology/Blood and Marrow Transplant, bDepartment of Experimental and Clinical …
Hyperviscosity Related to Waldenström Macroglobulinemia Treated with Plasmapheresis REFERENCES 1. Harrison's Principles of Internal Medicine, by J. Larry Jameson et al., McGraw-Hill Education, 2018, pp. 777–804. 2. Naoko Kudo, Masakatsu Usui, Yukiharu Nakabo, Ken-ichi Yoshida, Kenji Miki, Takashi Osafune, Keisuke Nishimura, Shinsaku Imashuku, "Waldenstrom’s Macroglobulinemia: A Report …
2021_MSCO_Poster Learn more: sph.umn.eduLearn more: sph.umn.edu Isavuconazonium sulfate use in multi-modal management of invasive Mucormycosis in four pediatric allogeneic hematopoietic cell transplant patients Asmaa Ferdjallah, MD; Kristina M. Nelson, PharmD, Kailey Meyer BA, Cathryn A. Jennissen, PharmD and Christen L. Ebens, MD MPH INTRODUCTION CASE #1: 2 Y/O FEMALE W/RHIZOPUS …
PowerPoint Presentation Successful treatment of COVID-19 vaccine induced idiopathic thrombocytopenic purpura in a 76-yo-gentleman taking Apixaban Haixia Qin, MD/PhD1 and Evan Mariash, MD2 1.Division of Hematology, Oncology and Transplantation; University of Minnesota Medical School, Department of Medicine 2.Department of hematology and oncology; Minneapolis VA Health Care System …
Slide 1 • cGVHD is the leading cause of non-relapse mortality (NRM) and morbidity after alloHCT • cGVHD frequently requires prolonged immunosuppressive therapy (IST) with > 50% of patients still on IST at 5 years • IST typically involves a slow taper of steroids often with flare of cGVHD, necessitating augmentation of previous therapy or addition of new IST • Studies …
PowerPoint Presentation The Development of Hypophysitis in a Patient Treated with Pemprolizumab Ashley Draisey, DO and Kristen Westenfield, MD; Abbott Northwestern Hospital, Minneapolis, MN CASE PRESENTATION We report a case of a middle-aged male with merkel cell carcinoma receiving pembrolizumab, a PD-1 inhibitor, who presented to the emergency department with two weeks of …
PowerPoint Presentation camB7-H3 Activates NK Cells in Presence of B7-H3+ Targets TriKE Function TriKE Structure Nicholas A. Zorko1*, Behiye Kodal1, Zachary B. Davis1, Alexander J. Lenvik1, Todd R. Lenvik1, Joshua Walker1, Daniel A. Vallera2, Svetlana Gaidarova3, Alejandro Garcia3, Tom T. Lee3, Ryan Bjordahl3, Bahram Valamehr3, Frank Cichocki1, Martin Felices1, Jeffrey S. Miller1 …
Slide 1 Insert Footer or Copyright Information Here Printed by I-SPY2 Trial The right drug, the right patient, the right time… now. BACKGROUND ispy2trial.org PURPOSE CONCLUSIONS METHODS I-SPY 2 is a multicenter, phase 2 clinical trial using response-adaptive randomization within biomarker subtypes to evaluate novel agents as neoadjuvant therapy for high-risk breast …